Singh Shweta A, Prakash Kelika, Kajal Kamal, Loganathan Sekar, K Nandakumar, Subramanian Rajkumar, Singh Anil, Choudhary Narendra S, Mukherjee Anindita, Viswanathan Premkumar Giri, Sindwani Gaurav, Ranade Sharmila, Malleeswaran Selva K, Raghu Arun, Mathiyazhagan Radhika, Venkatachalapathy Shamith, Pant Deepanjali, Srivastava Piyush, Kumar Lakshmi, Vohra Vijay, Rajkumar Akila, Narsimhan Gomathy, Goel Anupam, Aggarwal Vinayak, Kumar Ashok, Panackel Charles
Department of Anaesthesia and Critical Care - Center for Liver & Biliary Sciences (CLBS), Max Super Speciality Hospital (MSSH), Saket, New Delhi, India.
Department of Anaesthesiology, Pain Medicine & Critical Care AIIMS, New Delhi, India.
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102419. doi: 10.1016/j.jceh.2024.102419. Epub 2024 Oct 18.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among LT candidates and accounts for up to 40% of the overall mortality within one month. It is influenced by traditional and nontraditional risk factors related to end-stage liver disease. A large proportion of CLD patients have underlying cardiovascular disease (CVD) especially if the etiology is metabolic associated steatohepatitis. Despite the large number of liver transplantations being conducted in India, there is a lack of an evidence-based guidelines for screening of CVD in this patient population. This consensus statement from Liver Transplant Society of India (LTSI) is the first attempt for developing an evidence-based document on preoperative cardiac evaluation from India. A task force consisting of transplant-anesthesiologists, transplant hepatologists, liver transplant surgeon and cardiologists from high volume centres was formed which reviewed the existing evidence and literature and formulated graded recommendations. The document focuses on identification of underlying cardiac pathologies, risk stratification and optimisation of modifiable cardiac diseases. Implementation of best practices and optimal strategies should be encouraged to improve cardiovascular outcomes in these populations.
心血管疾病(CVD)是肝移植候选者发病和死亡的主要原因,在一个月内的总死亡率中占比高达40%。它受与终末期肝病相关的传统和非传统风险因素影响。很大一部分慢性肝病(CLD)患者患有潜在的心血管疾病(CVD),尤其是如果病因是代谢相关脂肪性肝炎。尽管印度进行了大量肝移植手术,但在这一患者群体中缺乏基于证据的心血管疾病筛查指南。印度肝移植协会(LTSI)的这份共识声明是印度首次尝试制定一份关于术前心脏评估的循证文件。一个由来自高容量中心的移植麻醉师、移植肝病学家、肝移植外科医生和心脏病学家组成的特别工作组成立了,该工作组审查了现有证据和文献并制定了分级建议。该文件侧重于识别潜在的心脏病理、风险分层以及可改变的心脏病的优化。应鼓励实施最佳实践和最佳策略,以改善这些人群的心血管结局。